Xiaofei Li1, Yan Yao1, Zhaoran Chen1, Siyang Fan1, Wei Hua1, Shu Zhang1, Xiaohan Fan1. 1. State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
BACKGROUND: The association between thyroid-stimulating-hormone (TSH) and prognosis of nonischemic dilated cardiomyopathy (NIDCM) in patients with normal thyroid function remains unclear. HYPOTHESIS: Our aim was to investigate the association between TSH and major adverse cardiovascular events in euthyroid NIDCM patients. METHODS: The original cohort consisted of 216 consecutive euthyroid NIDCM patients, with left ventricular ejection fraction (LVEF) ≤35%, who were observed from 2010 to 2013. Patients with persistent ventricular arrhythmia (VA) histories, amiodarone taken for VA prevention, or on heart transplant list within 1 year were excluded. A follow-up evaluation was performed, and VA events, heart failure (HF) exacerbation/heart transplant, cardiac death, or death from any cause were separately evaluated. RESULTS: A total of 184 patients were enrolled, and 97.8% (180/184) ultimately received follow-up evaluations. During the median 4.6-year follow-up, 24 VA events, 28 cardiac deaths, 30 all-cause deaths, 40 HF exacerbations, and 11 heart transplant events occurred. Serum TSH levels showed good predictive efficacies for VA events (area under the curve [AUC] = 0.702, 95% confidence interval [CI]: 0.629-0.767), and the risk of VA events increased, according to serum TSH quarters, as determined by Kaplan-Meier analysis (2.2% vs 13.4% vs 21.0% vs 30.0%, Q1-Q4, P = 0.011). Multivariable Cox analysis showed that patients at the Q4 level of serum TSH (>2.67 mIU/L) suffered an increased risk of VA events, compared with those at the Q1 level of TSH (hazard ratio [HR] = 15.88, 95% CI: 2.01-65.15) or those at the other three quarters (HR = 3.17, 95% CI: 1.38-7.26). However, the Q4 TSH level was not associated with other adverse cardiac events. CONCLUSION: An association between TSH levels and the risk of VA events may exist in euthyroid NIDCM patients.
BACKGROUND: The association between thyroid-stimulating-hormone (TSH) and prognosis of nonischemic dilated cardiomyopathy (NIDCM) in patients with normal thyroid function remains unclear. HYPOTHESIS: Our aim was to investigate the association between TSH and major adverse cardiovascular events in euthyroid NIDCM patients. METHODS: The original cohort consisted of 216 consecutive euthyroid NIDCM patients, with left ventricular ejection fraction (LVEF) ≤35%, who were observed from 2010 to 2013. Patients with persistent ventricular arrhythmia (VA) histories, amiodarone taken for VA prevention, or on heart transplant list within 1 year were excluded. A follow-up evaluation was performed, and VA events, heart failure (HF) exacerbation/heart transplant, cardiac death, or death from any cause were separately evaluated. RESULTS: A total of 184 patients were enrolled, and 97.8% (180/184) ultimately received follow-up evaluations. During the median 4.6-year follow-up, 24 VA events, 28 cardiac deaths, 30 all-cause deaths, 40 HF exacerbations, and 11 heart transplant events occurred. Serum TSH levels showed good predictive efficacies for VA events (area under the curve [AUC] = 0.702, 95% confidence interval [CI]: 0.629-0.767), and the risk of VA events increased, according to serum TSH quarters, as determined by Kaplan-Meier analysis (2.2% vs 13.4% vs 21.0% vs 30.0%, Q1-Q4, P = 0.011). Multivariable Cox analysis showed that patients at the Q4 level of serum TSH (>2.67 mIU/L) suffered an increased risk of VA events, compared with those at the Q1 level of TSH (hazard ratio [HR] = 15.88, 95% CI: 2.01-65.15) or those at the other three quarters (HR = 3.17, 95% CI: 1.38-7.26). However, the Q4 TSH level was not associated with other adverse cardiac events. CONCLUSION: An association between TSH levels and the risk of VA events may exist in euthyroid NIDCM patients.
Authors: Sabine M J M Straus; Jan A Kors; Marie L De Bruin; Cornelis S van der Hooft; Albert Hofman; Jan Heeringa; Jaap W Deckers; J Herre Kingma; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Jacqueline C M Witteman Journal: J Am Coll Cardiol Date: 2006-01-17 Impact factor: 24.094
Authors: Andrew E Epstein; John P DiMarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; David P Faxon; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick A Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2008-05-27 Impact factor: 24.094
Authors: Giuseppe Mancia; Stéphane Laurent; Enrico Agabiti-Rosei; Ettore Ambrosioni; Michel Burnier; Mark J Caulfield; Renata Cifkova; Denis Clément; Antonio Coca; Anna Dominiczak; Serap Erdine; Robert Fagard; Csaba Farsang; Guido Grassi; Hermann Haller; Anthony Heagerty; Sverre E Kjeldsen; Wolfgang Kiowski; Jean Michel Mallion; Athanasios Manolis; Krzysztof Narkiewicz; Peter Nilsson; Michael H Olsen; Karl Heinz Rahn; Josep Redon; José Rodicio; Luis Ruilope; Roland E Schmieder; Harry A J Struijker-Boudier; Pieter A van Zwieten; Margus Viigimaa; Alberto Zanchetti Journal: J Hypertens Date: 2009-11 Impact factor: 4.844
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur Heart J Date: 2008-09-17 Impact factor: 29.983
Authors: Charlotte van Noord; Wendy M van der Deure; Miriam C J M Sturkenboom; Sabine M J M Straus; Albert Hofman; Theo J Visser; Jan A Kors; Jacqueline C M Witteman; Bruno H Ch Stricker Journal: J Endocrinol Date: 2008-05-07 Impact factor: 4.286
Authors: T Shiga; N Hagiwara; H Ogawa; A Takagi; M Nagashima; T Yamauchi; Y Tsurumi; R Koyanagi; H Kasanuki Journal: Heart Date: 2008-08-26 Impact factor: 5.994
Authors: Johannes Wolfgang Dietrich; Rudolf Hoermann; John E M Midgley; Friederike Bergen; Patrick Müller Journal: Front Endocrinol (Lausanne) Date: 2020-10-26 Impact factor: 5.555